Status: Recruiting
Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy
This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.
Participants needed: 27
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: SparingVisionUpdated: Sep 8, 2026Locations: 3
Eligibility criteria
Age ≥ 18 years old at enrollment. [+5]
Participant participating in another clinical trial and receiving an investigati... [+26]